Literature DB >> 27692567

Prognostic impact of homocysteine levels and homocysteine thiolactonase activity on long-term clinical outcomes in patients undergoing percutaneous coronary intervention.

Ahmed Hassan1, Tomotaka Dohi2, Katsumi Miyauchi3, Manabu Ogita3, Makoto Kurano4, Ryunosuke Ohkawa5, Kazuhiro Nakamura4, Hiroshi Tamura3, Kikuo Isoda3, Shinya Okazaki3, Yutaka Yatomi4, Hiroyuki Daida3.   

Abstract

BACKGROUND: Numerous studies have reported the relationship between elevated homocysteine (Hcy) levels and the risk of coronary artery disease. However, there is insufficient information about the effects of Hcy levels on long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).
METHODS: In the Juntendo-registry cohort from 2003 to 2004, pre-procedural Hcy levels and Hcy thiolactonase activity (HTlase) were measured in 315 consecutive all-comer patients who underwent PCI for stable coronary artery disease or acute coronary syndrome (ACS). Receiver-operating characteristic (ROC) curves were created to assess the optimal cut-off values of Hcy and HTlase. Multivariable Cox proportional hazard regression analysis was used to identify the predictors of clinical outcome. The primary endpoint was all-cause mortality.
RESULTS: The patients' mean age was 66±9 years, and 82.5% were males. The median follow-up period was 10.5 years, and overall mortality was 24.5% (73 deaths). On ROC analysis, the optimal cut-off values of Hcy and HTlase were 13.5μmol/L and 230IU/L, respectively. Kaplan-Meier survival analysis showed associations of both higher Hcy levels and lower HTlase activity with worse prognosis (both log-rank p<0.001). On multivariate Cox proportional hazard regression analysis, higher Hcy was strongly associated with the primary outcome, and the adjusted hazard ratio was 3.3 (95% confidence interval, 1.8-5.6; p<0.001).
CONCLUSIONS: Pre-procedural high Hcy levels and low HTlase activity were associated with worse long-term mortality in Japanese patients undergoing PCI. Moreover, Hcy levels are strongly predictive for mortality, independent of traditional risk factors. This may have implications for risk stratification and the therapeutic approach in this PCI era.
Copyright © 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical outcome; Coronary artery disease; Homocysteine; Percutaneous coronary intervention

Mesh:

Substances:

Year:  2016        PMID: 27692567     DOI: 10.1016/j.jjcc.2016.08.013

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  5 in total

1.  Study on the Association of Homocysteine and C-Reactive Protein with Neurofunctional Changes in Patients with Acute Ischemic Stroke After Endovascular Stent Treatment.

Authors:  Qiong Chen; Wen-Tong Ling; Deng-Ke Han
Journal:  Neuropsychiatr Dis Treat       Date:  2022-04-13       Impact factor: 2.989

2.  Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial.

Authors:  K Borowczyk; J Piechocka; R Głowacki; I Dhar; Ø Midtun; G S Tell; P M Ueland; O Nygård; H Jakubowski
Journal:  J Intern Med       Date:  2018-09-23       Impact factor: 8.989

3.  Association of Hyperhomocysteinemia with Increased Coronary Microcirculatory Resistance and Poor Short-Term Prognosis of Patients with Acute Myocardial Infarction after Elective Percutaneous Coronary Intervention.

Authors:  Yang-Pei Peng; Ming-Yuan Huang; Yang-Jing Xue; Jia-Lin Pan; Cong Lin
Journal:  Biomed Res Int       Date:  2020-01-02       Impact factor: 3.411

4.  Prognostic impact of malnutrition on cardiovascular events in coronary artery disease patients with myocardial damage.

Authors:  Ryo Arikawa; Daisuke Kanda; Yoshiyuki Ikeda; Akihiro Tokushige; Takeshi Sonoda; Kazuhiro Anzaki; Mitsuru Ohishi
Journal:  BMC Cardiovasc Disord       Date:  2021-10-06       Impact factor: 2.298

5.  Prognostic ability of cystatin C and homocysteine plasma levels for long-term outcomes in very old acute myocardial infarction patients.

Authors:  Zhenhong Fu; Xia Yang; Mingzhi Shen; Hao Xue; Geng Qian; Feng Cao; Jun Guo; Wei Dong; Yundai Chen
Journal:  Clin Interv Aging       Date:  2018-07-03       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.